StockData

BioNTech vs Halozyme Therapeutics

BNTX and HALO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNTX and HALO compare

Halozyme Therapeutics grew revenue faster over the last twelve months (41.2% versus 4.3% for BioNTech).

Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −39.6% at BioNTech.

Halozyme Therapeutics scores higher on the StockData Score (13 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNTXHALO
Size and price
Market cap–$10.9B
Share price$84.86$95.97
Change, 1 year−17.7%37.0%
Change, 5 years−75.6%184%
Beta (5Y)1.150.82
Employees500423
StockData Score
Total score313 (better)
Valuation score00
Growth score14 (better)
Performance score15 (better)
Health score14 (better)
Dividend score00
Valuation
P/E–28.3×
P/S–6.5×
P/B–75.9×
EV/EBITDA–21.0×
P/FCF–13.5×
PEG–1.34
FCF yield–7.4%
Fair value–$69.98
Margin of safety–−37.1%
Growth
Revenue growth (TTM)4.3%41.2% (better)
Revenue growth, 5Y average42.9% (better)39.2%
Net income growth (TTM)–−25.8%
EPS growth (TTM)–−22.4%
EPS growth, 5Y average–23.0%
Profitability
Gross margin77.6%82.4% (better)
Operating margin−49.0%35.9% (better)
Net margin−39.6%24.9% (better)
FCF margin9.8%48.5% (better)
Return on equity–174%
Return on invested capital–21.7%
Financial health
Debt / equity–14.95
Net debt / EBITDA–3.24
Interest coverage−20.1×29.4× (better)
Current ratio7.54 (better)2.71
Altman Z-score–4.45
Piotroski F-score55
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions18.9%109%
Held by insiders58.2%1.3%
Insider net buying, 12 months−$89.8M−$49.8M (better)
Short interest, % of float–12.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.